Kensington Capital IV (KCAC) Secures Additional PIPE
by Marlena Haddad on 2022-09-09 at 5:39pm

Kensington Capital Acquisition Corp. IV (NYSE:KCAC) announced that it has tacked on an additional PIPE for its business combination with Amprius Technologies, Inc, just days after securing $13.375 million through a number of investors.

The SPAC has now entered into separate subscription agreements with certain entities that have previously invested in an affiliate of Amprius. The subscribers agreed to purchase an aggregate of 215,000 PIPE units at a price of $10.00 per PIPE unit, or $2,150,000, bringing the total PIPE to 1,552,500 units for gross proceeds of $15,525,000.

Kensington recently entered into separate subscription agreements on September 7 with multiple investors which agreed to purchase an aggregate of 1,337,500 units at $10.00 per unit for a total purchase price of $13.375 million.

Both PIPE units will consist of one share of Kensington common stock, and one warrant. The PIPE Warrants will also be substantially identical to the existing Kensington public warrants, except that the exercise price of each PIPE Warrant (for all PIPE subscribers) will be $12.50 per share instead of $11.50 per share, which is the exercise price for the existing Kensington public warrants.

Additionally, the average sales price of the New Amprius Common Stock for PIPE investors will need to exceed $20.00 per share instead of $18.00 per share for the existing public warrants for Kensington to be able to redeem the PIPE Warrants. Furthermore, the PIPE Warrants will not be listed on any securities exchange.

Today’s proceeds brings the total funding to $245.525 million, including the $230 million held in Kensington’s trust account. The parties expect to use the recent capital to help offset potential redemptions of the SPAC’s ordinary shares in connection with the proposed merger, and may be used by Kensington to help satisfy the minimum cash condition.

Kensington initially inked its $939 million deal with Amprius on May 12, 2022. Amprius, the Freemont, California-based silicon nanowire battery company manufacturers high-energy and high-power lithium-ion batteries.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved